2016 Fiscal Year Final Research Report
NKEA project: Next-Generation Therapy for NK/T-cell lymphoma in East Asia
| Project/Area Number |
26461418
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | NK/T細胞リンパ腫 / 新世代治療 / RT-2/3DeVIC療法 / 多施設共同研究 / 国際情報交換 / 東アジア |
|---|
| Outline of Final Research Achievements |
We conducted a retrospective study including patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL) diagnosed between 2000 and 2013 in 31 institutes in Japan (NKEA Part A) and elucidated the current status of next-generation therapy in clinical practice in Japan. The median age at diagnosis of all 358 patients was 58 years. Of 257 patients with localized ENKL, 66% received RT-DeVIC as first-line therapy. Efficacy and toxicity of RT-DeVIC in those patients were comparable to those in the JCOG0211 trial. Elevated pretreatment serum soluble IL-2 receptor was associated with short survival in those patients. L-asparaginase-containing chemotherapy was selected in 30% of 101 patients with untreated advanced ENKL.
|
| Free Research Field |
血液内科学 悪性リンパ腫
|
